Biota Holdings Limited - Price Analysis Snapshot

This Report features up to a ten-year record of the equity Price history for Biota Holdings Limited. Tabular results include the High, Low and Closing price for the quarter. There is also a calculation of percentage change in price for both Quarterly and Annual periods. Price values are adjusted for stock splits and dividends.

Biota Holdings Limited. The Group's principal activity is discovering and developing antiviral drugs. The Group's operation focuses on the development of Zanamivir, neuraminidase inhibitor for the treatment and prevention of influenza. Its research outcomes have included nucleoside analogues designed to treat hepatitis C virus (HCV) infections, licensed to Boehringer Ingelheim, and a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease. It operates in Australia.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report